



Vigilancia de la Poliomielitis en las Américas

**Cuadro No. 1
Análisis de las muestras de heces de casos
Últimas 52 semanas (2002/27-2003/26)**

| Lab. | País | Total* | SIN RESULTADOS | | | AISLAMIENTO DE ENTEROVIRUS | | | | | |
|-------|------|--------|----------------|----------|----------|----------------------------|----------|-------------------|------------|---------|---------|
| | | | Aún no en lab. | <28 Días | >28 Días | % Asla- miento | Negativo | Otros Enterovirus | Poliovirus | | |
| | | | | | | | | | Pendiente | Vacunal | Salvaje |
| BEL | BRA | 70 | 7 | 0 | 6 | 7,0 | 53 | 4 | 0 | 0 | 0 |
| CAR | DOR | 24 | 0 | 0 | 0 | 8,3 | 22 | 2 | 0 | 0 | 0 |
| | GUY | 6 | 0 | 0 | 0 | 16,7 | 5 | 1 | 0 | 0 | 0 |
| | HAI | 10 | 0 | 1 | 0 | 22,2 | 7 | 2 | 0 | 0 | 0 |
| | HON | 48 | 5 | 0 | 2 | 34,1 | 27 | 13 | 0 | 1 | 0 |
| | JAM | 7 | 0 | 0 | 0 | 0,0 | 7 | 0 | 0 | 0 | 0 |
| | SUR | 1 | 0 | 0 | 0 | 0,0 | 1 | 0 | 0 | 0 | 0 |
| | TRT | 8 | 0 | 0 | 0 | 0,0 | 8 | 0 | 0 | 0 | 0 |
| FIO | BRA | 401 | 68 | 1 | 15 | 19,2 | 256 | 59 | 0 | 2 | 0 |
| | PER | 67 | 4 | 0 | 9 | 29,6 | 38 | 16 | 0 | 0 | 0 |
| INC | COR | 12 | 1 | 0 | 0 | 18,2 | 9 | 2 | 0 | 0 | 0 |
| | ELS | 89 | 0 | 0 | 0 | 16,9 | 74 | 15 | 0 | 0 | 0 |
| | GUT | 76 | 0 | 6 | 3 | 11,9 | 59 | 8 | 0 | 0 | 0 |
| | NIC | 23 | 0 | 0 | 0 | 21,7 | 18 | 5 | 0 | 0 | 0 |
| | PAN | 2 | 1 | 0 | 0 | 0,0 | 1 | 0 | 0 | 0 | 0 |
| INDRE | MEX | 298 | 0 | 0 | 22 | 22,8 | 213 | 59 | 0 | 4 | 0 |
| INH | VEN | 84 | 0 | 6 | 0 | 3,8 | 75 | 3 | 0 | 0 | 0 |
| INS | COL | 105 | 0 | 8 | 16 | 19,8 | 65 | 12 | 1 | 3 | 0 |
| | ECU | 26 | 0 | 0 | 0 | 11,5 | 23 | 3 | 0 | 0 | 0 |
| ISP | CHI | 41 | 0 | 3 | 1 | 2,7 | 36 | 1 | 0 | 0 | 0 |
| MAL | ARG | 117 | 1 | 5 | 0 | 15,3 | 94 | 12 | 0 | 5 | 0 |
| | BOL | 54 | 1 | 0 | 14 | 7,7 | 36 | 3 | 0 | 0 | 0 |
| | CHI | 64 | 0 | 0 | 0 | 7,8 | 59 | 3 | 0 | 2 | 0 |
| | PAR | 18 | 1 | 0 | 0 | 11,8 | 15 | 1 | 0 | 1 | 0 |
| | URU | 2 | 0 | 0 | 0 | 50,0 | 1 | 0 | 0 | 1 | 0 |
| REC | BRA | 1 | 0 | 0 | 0 | 100,0 | 0 | 0 | 0 | 1 | 0 |
| TOTAL | | 1654 | 89 | 30 | 88 | 16,9 | 1202 | 224 | 1 | 20 | 0 |

* Cada muestra se refiere a un individuo

Muestras de casos solamente

**Cuadro No. 2
Poliovirus con diferenciación intratípica pendiente
Últimas 52 semanas (2002/27-2003/26)**

| LAB | PAIS | POLIOVIRUS | | | | | | | | | | | | TOTAL |
|-------|------|-------------------|----|----|------|-----------------------|----|----|------|-----------------------|----|----|------|-------|
| | | AÚN NO EN EL LAB, | | | | EN LAB < de 4 semanas | | | | EN LAB > de 4 semanas | | | | |
| | | P1 | P2 | P3 | Mez. | P1 | P2 | P3 | Mez. | P1 | P2 | P3 | Mez. | |
| COL | | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| TOTAL | | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |

Muestras de casos
solamente



Vigilancia de Parálisis Flácida Aguda

Vol, 18, No 26

Cuadro No. 1
Casos de parálisis flácida aguda bajo investigación
según semana de notificación

| PAIS | TOTAL | ACUM. | Semana | | | | | | | | | | |
|--------------|----------|------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|----------|
| | | | 2002 | 2003 | 1-4 | 5-8 | 9-12 | 13-16 | 17-20 | 21 | 22 | 23 | 24 |
| ARG | 0 | 11 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 5 | 1 |
| BOL | 0 | 15 | 0 | 1 | 7 | 2 | 1 | 2 | 1 | 1 | 0 | 0 | 0 |
| BRA | 1 | 92 | 5 | 5 | 6 | 31 | 24 | 6 | 12 | 1 | 1 | 1 | 0 |
| CAN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CAR | 0 | 12 | 1 | 2 | 3 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| CHI | 1 | 15 | 0 | 0 | 1 | 0 | 6 | 0 | 2 | 2 | 3 | 0 | 1 |
| COL | 1 | 29 | 1 | 3 | 3 | 3 | 6 | 4 | 2 | 3 | 3 | 0 | 1 |
| COR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CUB | 0 | 7 | 2 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| DOR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ECU | 0 | 7 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 2 | 0 | 0 | 0 |
| ELS | 0 | 8 | 0 | 0 | 0 | 2 | 5 | 0 | 0 | 1 | 0 | 0 | 0 |
| GUT | 1 | 9 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 1 | 2 |
| HAI | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| HON | 0 | 7 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 2 | 0 |
| MEX | 0 | 64 | 4 | 5 | 14 | 15 | 25 | 1 | 0 | 0 | 0 | 0 | 0 |
| NIC | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| PAN | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| PAR | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| PER | 0 | 19 | 2 | 1 | 2 | 4 | 6 | 4 | 0 | 0 | 0 | 0 | 0 |
| URU | 1 | 5 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| USA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| VEN | 0 | 5 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| TOTAL | 7 | 312 | 15 | 20 | 41 | 63 | 81 | 25 | 21 | 16 | 14 | 11 | 5 |

Cuadro No.2
Casos de PFA notificados, tasa por 100,000 <15 años,
% de casos investigados dentro 48 horas, % con 1 muestra
Adecuada y % de unidades notificando semanalmente

| PAIS | Total 2002 | | Ultimas 52 semanas (2002/27-2003/26) | | | | |
|--------------|-------------|-------------|--------------------------------------|-------------|-----------------|--------------|-----------------------|
| | CASOS | TASA | CASOS | TASA | % INV, <48 hrs, | %1 Mues-tra+ | % Sitios Notifi-caron |
| ARG | 129 | 1,19 | 128 | 1,16 | 91 | 70 | 100 |
| BOL | 64 | 1,95 | 54 | 1,60 | 96 | 63 | 0 |
| BRA | 636 | 1,23 | 530 | 1,02 | 95 | 75 | 90 |
| CAN | NR | NR | NR | NR | NR | NR | NR |
| CAR | 22 | 1,00 | 27 | 1,23 | 100 | 59 | 100 |
| CHI | 115 | 2,67 | 107 | 2,48 | 92 | 89 | 97 |
| COL | 121 | 0,86 | 115 | 0,82 | 72 | 77 | 55 |
| COR | 29 | 2,38 | 13 | 1,07 | 100 | 85 | NR |
| CUB | 37 | 0,83 | 23 | 0,51 | 100 | 100 | 96 |
| DOR | 36 | 1,12 | 25 | 0,74 | 100 | 76 | 91 |
| ECU | 43 | 1,00 | 42 | 0,97 | 69 | 93 | 84 |
| ELS | 110 | 4,82 | 101 | 4,38 | 72 | 85 | 61 |
| GUT | 72 | 1,58 | 78 | 1,71 | 91 | 91 | 44 |
| HAI | 12 | 0,38 | 11 | 0,34 | 64 | 45 | 40 |
| HON | 72 | 2,95 | 48 | 1,76 | 96 | 98 | 94 |
| MEX | 384 | 1,18 | 340 | 1,04 | 93 | 81 | 96 |
| NIC | 28 | 1,25 | 26 | 1,14 | 96 | 92 | 100 |
| PAN | 4 | 0,41 | 4 | 0,43 | 100 | 75 | 80 |
| PAR | 27 | 1,21 | 19 | 0,85 | 63 | 58 | 88 |
| PER | 96 | 1,12 | 73 | 0,85 | 100 | 89 | 99 |
| URU | 9 | 1,10 | 8 | 0,98 | 88 | 38 | 57 |
| USA | NR | NR | NR | NR | NR | NR | NR |
| VEN | 106 | 1,39 | 86 | 1,13 | 87 | 86 | 85 |
| Total | 2152 | 1,29 | 1858 | 1,11 | 90 | 79 | 82 |

+ Tomado dentro de los primeros 14 días del inicio de parálisis
 † Excluyendo Canadá y EUA
 NR - No reportes

Cuadro No. 3
Casos confirmados de poliomieltitis
por semana de inicio

Hasta la semana 26

| PAIS | TOTAL 2002 | Acumulado | |
|--------------|------------|-----------|----------|
| | | 2002 | 2003 |
| ARG | 0 | 0 | 0 |
| BOL | 0 | 0 | 0 |
| BRA | 0 | 0 | 0 |
| CAN | 0 | 0 | 0 |
| CAR | 0 | 0 | 0 |
| CHI | 0 | 0 | 0 |
| COL | 0 | 0 | 0 |
| COR | 0 | 0 | 0 |
| CUB | 0 | 0 | 0 |
| DOR | 0 | 0 | 0 |
| ECU | 0 | 0 | 0 |
| ELS | 0 | 0 | 0 |
| GUT | 0 | 0 | 0 |
| HAI | 0 | 0 | 0 |
| HON | 0 | 0 | 0 |
| MEX | 0 | 0 | 0 |
| NIC | 0 | 0 | 0 |
| PAN | 0 | 0 | 0 |
| PAR | 0 | 0 | 0 |
| PER | 0 | 0 | 0 |
| URU | 0 | 0 | 0 |
| USA | 0 | 0 | 0 |
| VEN | 0 | 0 | 0 |
| Total | 0 | 0 | 0 |

CAR Incluye informes de todos sus Países Miembros

Cuadro No. 4
Casos compatibles de poliomieltitis
por semana de inicio

Hasta la semana 26

| PAIS | TOTAL 2002 | Acumulado | |
|--------------|------------|-----------|----------|
| | | 2002 | 2003 |
| ARG | 0 | 0 | 0 |
| BOL | 2 | 1 | 0 |
| BRA | 1 | 0 | 0 |
| CAN | 0 | 0 | 0 |
| CAR | 0 | 0 | 0 |
| CHI | 0 | 0 | 0 |
| COL | 1 | 0 | 0 |
| COR | 0 | 0 | 0 |
| CUB | 0 | 0 | 0 |
| DOR | 0 | 0 | 0 |
| ECU | 1 | 0 | 0 |
| ELS | 0 | 0 | 0 |
| GUT | 0 | 0 | 1 |
| HAI | 0 | 0 | 0 |
| HON | 0 | 0 | 0 |
| MEX | 0 | 0 | 0 |
| NIC | 0 | 0 | 0 |
| PAN | 0 | 0 | 0 |
| PAR | 1 | 0 | 0 |
| PER | 0 | 0 | 0 |
| URU | 1 | 1 | 0 |
| USA | 0 | 0 | 0 |
| VEN | 0 | 0 | 0 |
| Total | 7 | 2 | 1 |

CAR Incluye informes de todos sus Países Miembros

LA POLIOMIELITIS HA SIDO ERRADICADA DE LAS AMÉRICAS
 El último caso con poliovirus salvaje fue detectado el 5 de septiembre de 1991, en Perú